Market Overview

Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ELIQUIS

Related BMY
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?
Bristol-Myers Squibb's (Investor's Business Daily)

Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced the results of the Phase 3
AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS®
(apixaban) over a one-year period compared to placebo for the prevention
of recurrent venous thromboembolism (VTE) in 2,486 patients who had
already completed 6 to 12 months of anticoagulation treatment for VTE,
including deep vein thrombosis (DVT) or pulmonary embolism (PE). In the
trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily,
demonstrated superiority versus placebo in the reduction of the
composite endpoint of symptomatic, recurrent VTE and death from any
cause (11.6% in the placebo group, compared with 3.8% and 4.2% in the

See full press release

Posted-In: News Guidance Contracts Management


Related Articles (BMY + PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters